middle.news
Telix and Regeneron Launch $40M Radiopharma Partnership Targeting Hard-to-Treat Cancers
8:40am on Monday 13th of April, 2026 AEST
•
Healthcare
Read Story
Telix and Regeneron Launch $40M Radiopharma Partnership Targeting Hard-to-Treat Cancers
8:40am on Monday 13th of April, 2026 AEST
Key Points
50/50 cost and profit-sharing on initial four radiopharma programs
Telix to receive $40 million upfront plus up to $2.1 billion in milestones
Collaboration leverages Telix’s radiopharma and Regeneron’s antibody platforms
Focus on solid tumors and companion diagnostics for precision oncology
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE